On February 9, 2012, a three judge panel of the United States Court of Appeals for the Federal Circuit (Federal Circuit) confirmed that the filing of an Abbreviated New Drug Application (ANDA) directed to an FDA-approved unpatented use of a pharmaceutical composition does not constitute infringement of method patents covering other FDA-approved uses of the same composition.